Please assess the completion status of the following clinical trial:

Trial Title: Pirfenidone and Advanced Liver Fibrosis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients with chronic liver disease whose fibrosis continued to progress despite abstaining from alcohol (ALD), achieving sustained virologic response (VHC), or otherwise maintaining stable disease (NAFLD, AIH)..~2. Advanced liver fibrosis defined as fibrosis grade 3 or grade 4 according to METAVIR scale based in two non-invasive liver fibrosis evaluation methods (FibroScan and Fibrotest).~3. Stable liver disease.~Exclusion Criteria:~1. Patients with mild fibrosis (F1-F2)~2. Under medication with colchicine, silymarin, non-steroidal anti-inflammatory drugs, and any hepatotoxic drug.~3. Decompensation based on a history of hepatic encephalopathy, esophageal variceal bleeding, or ascites in the previous 6 months~4. HIV, Hepatitis B virus (HBV) or any active infectious processes not of a self-limited nature.~5. Concomitant or prior history of malignancy other than curatively-treated skin cancer or surgically-cured in situ carcinoma of the cervix.~6. Hemoglobinopathy or any disease associated with hemolysis.~7. History of significant cardiac or pulmonary disease that could be exacerbated by anemia.~8. Liver masses detected by baseline scanner or Alpha-fetoprotein \>100 ng/L.~9. Pregnancy.~10. Alcohol or intravenous drug abuse within the previous year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Antifibrotic plus standard of care treatment (Type: EXPERIMENTAL): Prolonged release pirfenidone formulation in combination with standard of care treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).